NO20072302L - Modulatorer av hepatocyttvekstfaktoraktivator - Google Patents

Modulatorer av hepatocyttvekstfaktoraktivator

Info

Publication number
NO20072302L
NO20072302L NO20072302A NO20072302A NO20072302L NO 20072302 L NO20072302 L NO 20072302L NO 20072302 A NO20072302 A NO 20072302A NO 20072302 A NO20072302 A NO 20072302A NO 20072302 L NO20072302 L NO 20072302L
Authority
NO
Norway
Prior art keywords
growth factor
modulators
hepatocyte growth
factor activator
activator
Prior art date
Application number
NO20072302A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel K Kirchhofer
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20072302L publication Critical patent/NO20072302L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20072302A 2004-10-04 2007-05-03 Modulatorer av hepatocyttvekstfaktoraktivator NO20072302L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61565704P 2004-10-04 2004-10-04
PCT/US2005/036300 WO2006042173A2 (en) 2004-10-04 2005-10-03 Modulators of hepatocyte growth factor activator

Publications (1)

Publication Number Publication Date
NO20072302L true NO20072302L (no) 2007-06-28

Family

ID=36148972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072302A NO20072302L (no) 2004-10-04 2007-05-03 Modulatorer av hepatocyttvekstfaktoraktivator

Country Status (16)

Country Link
US (4) US20060147451A1 (zh)
EP (1) EP1809673B1 (zh)
JP (2) JP4937127B2 (zh)
KR (1) KR101252306B1 (zh)
CN (1) CN101035810B (zh)
AU (1) AU2005294146B2 (zh)
BR (1) BRPI0515670A (zh)
CA (1) CA2577598C (zh)
ES (1) ES2398528T3 (zh)
HK (1) HK1105006A1 (zh)
IL (1) IL181450A0 (zh)
NO (1) NO20072302L (zh)
NZ (1) NZ553327A (zh)
RU (1) RU2418004C2 (zh)
WO (1) WO2006042173A2 (zh)
ZA (1) ZA200701789B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035810B (zh) 2004-10-04 2011-04-06 健泰科生物技术公司 肝细胞生长因子激活剂的调控物
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
SI2056874T1 (sl) * 2006-08-21 2012-12-31 F. Hoffmann-La Roche Ag Terapija tumorjev s protitelesom proti vegf
MX2009008430A (es) * 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
US20170204191A1 (en) * 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
US8759491B2 (en) * 2009-10-19 2014-06-24 Genentech, Inc. Modulators of hepatocyte growth factor activator
ES2534646T3 (es) 2009-10-22 2015-04-27 F. Hoffmann-La Roche Ag Anticuerpos anti-hepsina y métodos de uso de los mismos
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
US10882920B2 (en) 2014-11-19 2021-01-05 Genentech, Inc. Antibodies against BACE1 and use thereof for neural disease immunotherapy
US11746159B2 (en) 2015-02-10 2023-09-05 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
WO2023172863A1 (en) * 2022-03-07 2023-09-14 Elixiron Immunotherapeutics (hong Kong) Limited Anti-cd36 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
CA2102463A1 (en) * 1992-11-05 1994-05-06 Mitsubishi Chemical Corporation Protein and gene encoding said protein
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
JP4090236B2 (ja) * 2000-12-05 2008-05-28 三菱化学株式会社 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
US7045602B2 (en) * 2000-12-05 2006-05-16 Mitsubishi Chemical Corporation Specific antibody directed to active hepatocyte growth factor activator and method for using the same
CN101035810B (zh) 2004-10-04 2011-04-06 健泰科生物技术公司 肝细胞生长因子激活剂的调控物

Also Published As

Publication number Publication date
US20130217862A1 (en) 2013-08-22
KR101252306B1 (ko) 2013-04-08
US20090047291A1 (en) 2009-02-19
IL181450A0 (en) 2007-07-04
WO2006042173A2 (en) 2006-04-20
CA2577598A1 (en) 2006-04-20
JP2008515918A (ja) 2008-05-15
RU2007116806A (ru) 2008-11-10
EP1809673A2 (en) 2007-07-25
CN101035810A (zh) 2007-09-12
BRPI0515670A (pt) 2008-07-29
NZ553327A (en) 2010-02-26
JP5554298B2 (ja) 2014-07-23
EP1809673B1 (en) 2012-11-28
JP2012025752A (ja) 2012-02-09
ZA200701789B (en) 2008-11-26
KR20070102470A (ko) 2007-10-18
US20060147451A1 (en) 2006-07-06
ES2398528T3 (es) 2013-03-19
JP4937127B2 (ja) 2012-05-23
US7825221B2 (en) 2010-11-02
RU2418004C2 (ru) 2011-05-10
AU2005294146B2 (en) 2011-09-15
AU2005294146A1 (en) 2006-04-20
HK1105006A1 (en) 2008-02-01
WO2006042173A3 (en) 2006-08-17
US8969528B2 (en) 2015-03-03
CN101035810B (zh) 2011-04-06
CA2577598C (en) 2016-09-20
US8399629B2 (en) 2013-03-19
US20110098449A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
NO20072302L (no) Modulatorer av hepatocyttvekstfaktoraktivator
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
DK1778236T3 (da) Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
IL244803B (en) Human anti-beta antibodies and their use
TW200732349A (en) Anti-OX40L antibodies and methods using same
DK1879573T3 (da) Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
EA200700702A1 (ru) Аналоги локсапина и способы их применения
CR9869A (es) Compuestos activos en ppar
MY162181A (en) Compositions and methods for modulating hemostasis
NO20090046L (no) Preparater og fremgangsmater for modulering av vaskulaer utvikling
DK1761497T3 (da) Azadecalinglucocorticoidreceptormodulatorer
NO20091083L (no) Organiske forbindelser
TW200613731A (en) Flow modulation devices
ATE518010T1 (de) Aktive oberflächengekoppelte polymerasen
CO6351784A2 (es) Formas cristalinas de dimetoxi-docetaxel y sus procedimeintos de preparacion
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
TW200640924A (en) VEGF-R2 inhibitors and methods
DK1910395T3 (da) Sammensætninger og fremgangsmåder til modulation af SMN2-splejsning
BRPI0514586A (pt) triazolftalazinas
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200500206A1 (ru) СПОСОБ И КОМПОЗИЦИИ ДЛЯ МОДУЛЯЦИИ РАЗВИТИЯ И ФУНКЦИИ КЛЕТОК Т-ХЕЛПЕРОВ (Тх)
EA200701293A1 (ru) Терапевтическая композиция фактора роста кератиноцитов
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application